Natco pharma share price

Pharma industry increasingly adopting sustainable practices Natco Pharma has recorded consolidated revenue of ₹2,812 crore for the year ended March 31, 2023, as against Rs 2,044 crore last year, registering 37.6 per cent growth, with a consolidated net profit of ₹715 crore as against ₹170 crore last year. The increase in revenue and profits for the year was driven by business growth in the US market, as also Canada and Brazil, where it has subsidiaries. Also read: It is also in the process of ramping up subsidiary business overseas and setting up an arm in Colombia with an investment of up to $100,000 and another in Indonesia. As part of the ‘multi-pronged’ strategy to strengthen international business, it is also looking to buy an asset in the UK, the CEO said, adding, “The subsidiaries are doing extremely well. The future of the business is the subs.’‘ In the FY23 balance sheet, they contributed about Rs 555 crore of revenue. Natco is also trying to globalise and use its R&D pipeline to extend to a multiple number of markets. • Comments will be moderated by The Hindu BusinessLine editorial team. • Comments that are abusive, personal, incendiary or irrelevant cannot be published. • Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and'). • We may remove hyperlinks within comments. • Please use a genuine email ID and provide ...

Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/43459/natco-pharma-ltd/ Get Natco Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF; and agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Return on average equity - 5 year average 12.39 Net Income/employee - trailing 12 month - Revenue/employee - most recent fiscal year - Return on investment - most recent fiscal year 15.26 Return on average assets - most recent fiscal year 13.29 Receivables turnover - most recent fiscal year 3.67 Return on investment - trailing 12 month 15.26 Return on average assets - trailing 12 month 13.29 Inventory turnover - most recent fiscal year 0.78 Inventory turnover - trailing 12 month 0.83 Revenue/employee - trailing 12 month - Return on average assets - 5 year average 10.34 Net Income/employee - most recent fiscal year - Return on average equity - trailing 12 month 15.66 Receivables turnover - trailing 12 month 3.67 Asset turnover - most recent fiscal year 0.50 Asset turnover - trailing 12 month 0.50 Return on average equity - most recent fiscal year 15.66 Return on investment - 5 year average 12.04

• Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of -0.03% as compared to Nifty Midcap 100 which gave a return of 145.85%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated -0.03% return as compared to Nifty Pharma which gave investors 29.91% return over 3 year time period. (as of last trading session) NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 16.08 2.36 14.67 17.61 12.64 11.49 32.37 26.42 39.18 4.39 0.03 0.00 42.62 7.04 16.52 19.71 11.53 19.84 18.77 13.01 53.00 2.80 0.22 0.00 21.28 2.09 9.81 13.89 8.89 11.59 30.85 21.54 47.44 9.46 0.00 0.00 30.03 7.12 23.70 31.27 20.92 17.44 42.16 30.68 16.16 6.37 0.04 0.00 35.40 2.77 7.82 9.58 5.53 6.97 7.70 6.59 17.40 1.78 0.15 0.00 Add More • Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of -0.03% as compared to Nifty Midcap 100 which gave a return of 145.85%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated -0.03% return as compared to Nifty Pharma which gave investors 29.91% return over 3 year time period. (as of last trading session) Meeting Date Announced on Purpose Details May 29, 2023 May 19, 2023 Board Meeting Audited Results Mar 08, 2023 Mar 02, 2023 Board Meeting Buy Back of shares Feb 09, 2023 Jan 31, 2023 Board Meeting Quarterly Results & Interim Dividend Nov 10, 2022 Oct 31, 2022 Board Meeting Quarterly Results & 2nd Interim Dividend Aug 09, 2022 Aug 01, ...

Date Open High Low Close* Adj Close** Volume Jun 16, 2023 650.50 654.90 627.05 630.35 630.35 1,008,381 Jun 15, 2023 620.00 643.80 620.00 639.55 639.55 1,151,271 Jun 14, 2023 621.00 625.00 618.65 619.95 619.95 299,856 Jun 13, 2023 625.30 625.30 618.20 620.55 620.55 160,407 Jun 12, 2023 623.80 625.95 616.60 622.05 622.05 391,878 Jun 09, 2023 625.50 625.85 621.00 623.80 623.80 301,054 Jun 08, 2023 628.00 628.40 620.85 623.25 623.25 263,258 Jun 07, 2023 620.40 625.40 620.35 622.45 622.45 271,111 Jun 06, 2023 631.00 634.45 619.00 620.30 620.30 886,858 Jun 05, 2023 634.90 644.40 628.00 630.70 630.70 552,968 Jun 02, 2023 625.00 636.30 623.15 627.80 627.80 1,114,400 Jun 01, 2023 623.90 634.00 618.90 622.95 622.95 663,142 May 31, 2023 623.55 626.80 615.75 618.80 618.80 545,569 May 30, 2023 649.80 649.80 615.50 619.50 619.50 1,055,388 May 29, 2023 637.75 659.70 629.10 633.10 633.10 2,029,363 May 26, 2023 622.00 640.00 617.40 629.80 629.80 270,892 May 25, 2023 619.00 625.00 609.15 620.55 620.55 250,608 May 24, 2023 620.10 624.45 616.95 618.35 618.35 64,082 May 23, 2023 617.15 630.00 617.15 620.10 620.10 59,182 May 22, 2023 617.95 628.70 616.00 619.55 619.55 142,462 May 19, 2023 624.00 625.00 615.00 617.85 617.85 117,931 May 18, 2023 622.60 631.00 622.40 625.50 625.50 134,666 May 17, 2023 626.00 630.00 615.50 622.40 622.40 115,267 May 16, 2023 630.00 640.20 620.50 625.10 625.10 228,394 May 15, 2023 620.25 633.00 615.25 630.30 630.30 207,062 May 12, 2023 636.00 640.50 620.05 623.30 623...

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the R...

Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market. • India formulations mainly comprise oncology products (38 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units • Maiden entry into crop protection was via launch of pheromone product, Natmate PBW for controlling pink bollworm in cotton • FY22 revenue break-up - domestic business: 25%, international business: 62% (mainly from the US), APIs: 13% Revenues were buoyed by gains from gRevlimid, in the export formulation segment while Natco booked inventory write-off for Covid products of ₹ 232 crore and provisioning towards estimated credit loss of ₹ 46 crore. • Sales were up 80% YoY to ₹ 597 crore • Adjusted EBITDA for one-offs was at ₹ 259 crore, with margins at 43% • Booked loss of ₹ 50 crore vs. profit of ₹ 53 crore in Q4FY21 Q4FY23 Quarterly & FY23 Annual Result Announced for Natco Pharma Ltd. Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results: • Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth. • The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22. • The increase in revenue and profits for FY23 was driven by business growth in the US market and gro...

• Company is virtually debt free. • Company has a healthy Interest coverage ratio of 12.7218045112782. • The Company has been maintaining an effective average operating margins of 29.6700319019263% in the last 5 years. • Company has a healthy liquidity position with current ratio of 3.34490171990172. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 514.1 805.7 351.1 413 781.2 Total Expenditure 551.8 426.3 281 345.5 453.5 Operating Profit -37.7 379.4 70.1 67.5 327.7 Other Income 10.4 33.2 16.2 18.6 17.5 Interest 4.2 2.7 1.7 3 1.2 Depreciation 35.6 36.9 38.3 38.1 37.6 Exceptional Items 0 0 0 0 0 Profit Before Tax -67.1 373 46.3 45 306.4 Tax -5.8 65 8.6 7.7 52.3 Profit After Tax -61.3 308 37.7 37.3 254.1 Adjusted EPS (Rs) -3.36 16.88 2.07 2.04 13.92 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 2091.3 1986.3 1790.2 1653.5 1767.8 Total Expenditure 1162.9 1169.8 1212.2 1238.3 1554.8 Operating Profit 928.4 816.5 578 415.2 213 Other Income 39.4 129.8 123.8 103.5 94.6 Interest 14.7 18.8 20.6 11.3 13.3 Depreciation 65.5 80.1 98.1 115.2 138.4 Exceptional Items 0 0 0 0 0 Profit Before Tax 887.6 847.4 583.1 392.2 155.9 Tax 189.4 180.3 108.6 82.7 16.8 Net Profit 698.2 667.1 474.5 309.5 139.1 Adjusted EPS (Rs.) 37.84 36.55 26.07 16.96 7.62 Balance Sheet (All Figures are in Crores.) Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Equity and Liabilit...

Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market. • India formulations mainly comprise oncology products (38 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units • Maiden entry into crop protection was via launch of pheromone product, Natmate PBW for controlling pink bollworm in cotton • FY22 revenue break-up - domestic business: 25%, international business: 62% (mainly from the US), APIs: 13% Revenues were buoyed by gains from gRevlimid, in the export formulation segment while Natco booked inventory write-off for Covid products of ₹ 232 crore and provisioning towards estimated credit loss of ₹ 46 crore. • Sales were up 80% YoY to ₹ 597 crore • Adjusted EBITDA for one-offs was at ₹ 259 crore, with margins at 43% • Booked loss of ₹ 50 crore vs. profit of ₹ 53 crore in Q4FY21 Q4FY23 Quarterly & FY23 Annual Result Announced for Natco Pharma Ltd. Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results: • Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth. • The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22. • The increase in revenue and profits for FY23 was driven by business growth in the US market and gro...

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the R...